2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1218

Extensive Genetic Overlap of Traits Related to Gout, Hyperuricemia and Its Comorbidities
Abstract Number: 2129

Extracellular Adenosine Deficiency Plays a Role in the Pathogenesis of Osteoarthritis (OA) and Adenosine Replacement Prevents Post-Traumatic Osteoarthritis
Abstract Number: 283

Extracellular Histidyl-tRNA Synthetase in Myositis
Abstract Number: 1127

Extracellular Macrophage Migration Inhibitory Factor Is Essential for Hypoxia-Induced Angiogenesis in a Hypoxia Inducible Factor Independent Manner
Abstract Number: 1114

Extracellular Vesicles in the Circulating of Rheumatoid Arthritis Patients Are Pro-Inflammatory
Abstract Number: 820

EZH2 Modulates Angiogenesis and Fibrosis in Scleroderma
Abstract Number: 2019

Faces in Motion: Clinical Subtyping in Scleroderma Using Changes in Forced Vital Capacity
Abstract Number: 2370

Factors Affecting Interval Changes in Perceived Fatigue over Five Years in Patients with Rheumatoid Arthritis Compared with Osteoarthritis
Abstract Number: 635

Factors Associated to Lack of Adherence to Subcutaneous Biological Medications in Patients with Rheumatoid Arthritis from Spain. Arco Study
Abstract Number: 563

Factors Associated with Cognitive Impairment in Korean Adults with Rheumatoid Arthritis
Abstract Number: 1805

Factors Associated with Complete Remission in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study in One Center
Abstract Number: 565

Factors Associated with Gastrointestinal Tolerance in Patients with Rheumatoid Arthritis and Methotrexate Daily Doses
Abstract Number: 1930

Factors Associated with Glucocorticoid Exposure in ANCA-Associated Vasculitis
Abstract Number: 3094

Factors Associated with Initial or Subsequent Choice of Biologic Disease Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis
Abstract Number: 779

Factors Determining Hydroxychloroquine Serum Levels in a Cohort of Chinese Patients with Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].